Recent research highlighting anti-CTLA-4 combination strategies, such as Treg cell depletion, utilization of cancer vaccines, and consideration of the gut microbiome, has revealed promising preclinical results that are poised for subsequent investigation in patients. The gene discussed is CTLA4; the disease is cancer.